Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Or
Select a campus/region
  • REMODEL II

    To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis

    Investigator
    Torge Rempe
    Ages
    18 Years - 55 Years
    Sexes
    All
  • TREAT-MS

    FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early…

    Investigator
    Torge Rempe
    Ages
    18 Years - 60 Years
    Sexes
    All
  • SANOFI 16035 PERSEUS

    Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical…

    Investigator
    Torge Rempe
    Ages
    18 Years - 55 Years
    Sexes
    All
  • CELGENE RPC 1063

    This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no disease modifying…

    Investigator
    Torge Rempe
    Ages
    18 Years - 65 Years
    Sexes
    All